Secondary endpoints
At 4 weeks, compared to patients in the placebo arm, patients receiving clonidine had a larger reduction of the mean total QUIP-RS score (7.9 versus 2.9 points). At 8 weeks, this difference became greater; 11.0 points under clonidine versus 3.6 under placebo (Fig. QUIP-RS total score at baseline, 4 and 8 weeks for placebo and clonidine groupThe frequency of success in reducing QUIP-RS at 4 weeks did not differ between groups (4/20 in the placebo arm (20%) and 4/19 in the clonidine arm (21%).In the mixed effect model, the estimated mean difference of QUIP-RS evolution between clonidine and placebo groups was  – 3.8 (95%CI [ – 7.2; 0.4]) (see details in supplemental data).There was no worsening of motor or non-motor manifestations under clonidine.The MDS UPDRS total and component scores, STAI-Y-A and B, ECMP, and the Epworth scale remained stable at 8 weeks in the ITT population. The PDQ39 score was better at 8 weeks than inclusion in the clonidine group and worse in the placebo group (Table Secondary objectives